SAB BIO to Participate in Upcoming Investor Conferences
(NasdaqGM:SABS),(NasdaqGM:SABSW), MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) — SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti-thymocyte immunoglobulin (hIgG) that potentially delays the onset or progression of type 1 diabetes (T1D), today announced that members of its management team […]